Pub Date : 2023-11-18DOI: 10.29011/2577-1507.100130
Davoud Amiri, Ali Moghaddam
The opioid crisis in North America, particularly the United States and Canada, has been characterized by increasing methadone distribution, overdose deaths and diversion, although recent efforts have seen declines in some areas. Canada’s prescription opioid dispensing increased until 2012, after which areas such as Ontario saw significant declines. The United States experienced a staggering 345% increase in opioid-related deaths from 2001-2016, heavily affecting people aged 25-34. This growing epidemic is further highlighted by the U.S. National Survey, which shows that 8.9% of Americans aged 12 or older engaged in illicit drug use recently. Research links opioid sales to overdose deaths, highlighting the dangers of inappropriate prescription practices. To address this, Medication-Assisted Treatment (MAT), behavioral therapies and support groups are promoted. Anti-stigma interventions such as acceptance and commitment therapy and motivational interviewing have been shown to be effective. A consistent pattern observed in cities such as Philadelphia and San Francisco indicate that young heroin addicts often switch from pharmaceutical opioids to heroin, driven by the economics of drug supply. To address opioid use disorders, primary care has recognized MAT as critical, with new innovative models such as multi-level care and stakeholder engagement. Nevertheless, barriers such as stigma and lack of expertise pose challenges, highlighting the urgent need for refined strategies and models tailored to different primary care settings.
{"title":"The Opioid Epidemic in Numbers: A Meta-Analytic Review of Mortality, findings, and Implications for Prevention","authors":"Davoud Amiri, Ali Moghaddam","doi":"10.29011/2577-1507.100130","DOIUrl":"https://doi.org/10.29011/2577-1507.100130","url":null,"abstract":"The opioid crisis in North America, particularly the United States and Canada, has been characterized by increasing methadone distribution, overdose deaths and diversion, although recent efforts have seen declines in some areas. Canada’s prescription opioid dispensing increased until 2012, after which areas such as Ontario saw significant declines. The United States experienced a staggering 345% increase in opioid-related deaths from 2001-2016, heavily affecting people aged 25-34. This growing epidemic is further highlighted by the U.S. National Survey, which shows that 8.9% of Americans aged 12 or older engaged in illicit drug use recently. Research links opioid sales to overdose deaths, highlighting the dangers of inappropriate prescription practices. To address this, Medication-Assisted Treatment (MAT), behavioral therapies and support groups are promoted. Anti-stigma interventions such as acceptance and commitment therapy and motivational interviewing have been shown to be effective. A consistent pattern observed in cities such as Philadelphia and San Francisco indicate that young heroin addicts often switch from pharmaceutical opioids to heroin, driven by the economics of drug supply. To address opioid use disorders, primary care has recognized MAT as critical, with new innovative models such as multi-level care and stakeholder engagement. Nevertheless, barriers such as stigma and lack of expertise pose challenges, highlighting the urgent need for refined strategies and models tailored to different primary care settings.","PeriodicalId":285733,"journal":{"name":"Journal of Addiction and Therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139261602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-28DOI: 10.29011/2577-1507.100021
{"title":"HIV/AIDS and Substance Abuse Primary Prevention in at Risk Adolescents: A Program Analysis","authors":"","doi":"10.29011/2577-1507.100021","DOIUrl":"https://doi.org/10.29011/2577-1507.100021","url":null,"abstract":"","PeriodicalId":285733,"journal":{"name":"Journal of Addiction and Therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127237034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-05-11DOI: 10.29011/2577-1507/100022
Mallori M. Henceroth, Joseph R. Campbell, C. Mayra, elario, Joanne Elayoubi, C. Aguilar, D. Malin
Introduction: Severity of withdrawal syndrome in women during smoking cessation has reportedly been influenced by menstrual phase. There are few studies of female rats with their four-day estrous cycle. Methods: Histological examination determined the precise estrous phase at time of testing. The subjects were 14 qualifying female rats and 8 male rats, all five to six months old. Slides of vaginal fluid were examined for estrous phaseidentifying cell types. Nicotine withdrawal was evaluated at either the proestrus phase (n=7), a follicular portion of the cycle, and the metestrus phase (n=7) a luteal portion. Rats were continuously infused with 9 mg/kg/day s.c. nicotine bitartrate. On the seventh day, each subject was challenged with 1 mg/kg of the nicotinic antagonist mecamylamine, a dose that precipitates a vigorous withdrawal syndrome only in nicotine-dependent rats. Subjects were observed over 30 min. on a standard checklist of somatically expressed withdrawal behaviors. Results: Male rats displayed 26.00 ± 3.64 withdrawal signs (M ± SEM), while female rats in proestrus exhibited a similar 28.86 ± 3.39 signs. Female rats in metestrus displayed 41.57 ± 5.38 signs. One-way ANOVA revealed a significant difference among groups, p=0.039. Post hoc comparisons revealed significant differences between metestrus and proestrus females, p=0.049 and between metestrus females and males, p=0.016, but not between proestrus females and males. Conclusions: The results are consistent with reports of menstrual phase influence on withdrawal severity in smoking cessation, providing a laboratory model for studying this issue and its potential treatment. Implications: In the large literature on nicotine withdrawal in the rat, there are relatively few studies on female rats and hardly any on the effects of the estrous cycle on physical dependence and withdrawal. The results are consistent with reports on the menstrual cycle affecting withdrawal severity in women undergoing smoking cessation, supporting the translational relevance of the rat nicotine dependence model. The methods utilized here expand the ability of rat physical dependence models to compare the sexes and the estrous phases in nicotine physical dependence and withdrawal.
{"title":"Effect of Sex and Estrous Cycle on Nicotine withdrawal Syndrome in the Rat","authors":"Mallori M. Henceroth, Joseph R. Campbell, C. Mayra, elario, Joanne Elayoubi, C. Aguilar, D. Malin","doi":"10.29011/2577-1507/100022","DOIUrl":"https://doi.org/10.29011/2577-1507/100022","url":null,"abstract":"Introduction: Severity of withdrawal syndrome in women during smoking cessation has reportedly been influenced by menstrual phase. There are few studies of female rats with their four-day estrous cycle. \u0000Methods: Histological examination determined the precise estrous phase at time of testing. The subjects were 14 qualifying female rats and 8 male rats, all five to six months old. Slides of vaginal fluid were examined for estrous phaseidentifying cell types. Nicotine withdrawal was evaluated at either the proestrus phase (n=7), a follicular portion of the cycle, and the metestrus phase (n=7) a luteal portion. Rats were continuously infused with 9 mg/kg/day s.c. nicotine bitartrate. On the seventh day, each subject was challenged with 1 mg/kg of the nicotinic antagonist mecamylamine, a dose that precipitates a vigorous withdrawal syndrome only in nicotine-dependent rats. Subjects were observed over 30 min. on a standard checklist of somatically expressed withdrawal behaviors. \u0000Results: Male rats displayed 26.00 ± 3.64 withdrawal signs (M ± SEM), while female rats in proestrus exhibited a similar 28.86 ± 3.39 signs. Female rats in metestrus displayed 41.57 ± 5.38 signs. One-way ANOVA revealed a significant difference among groups, p=0.039. Post hoc comparisons revealed significant differences between metestrus and proestrus females, p=0.049 and between metestrus females and males, p=0.016, but not between proestrus females and males. \u0000Conclusions: The results are consistent with reports of menstrual phase influence on withdrawal severity in smoking cessation, providing a laboratory model for studying this issue and its potential treatment. \u0000Implications: In the large literature on nicotine withdrawal in the rat, there are relatively few studies on female rats and hardly any on the effects of the estrous cycle on physical dependence and withdrawal. The results are consistent with reports on the menstrual cycle affecting withdrawal severity in women undergoing smoking cessation, supporting the translational relevance of the rat nicotine dependence model. The methods utilized here expand the ability of rat physical dependence models to compare the sexes and the estrous phases in nicotine physical dependence and withdrawal.","PeriodicalId":285733,"journal":{"name":"Journal of Addiction and Therapies","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-05-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116894900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：